Articles tagged with Cardiology
A recent study published in Scientific Reports found that swimming is more effective than running in promoting healthy heart growth and improving heart muscle strength. Swimming promoted greater modulation of microRNAs, which control various heart adaptations, compared to running training.
Seven original research studies on cardiometabolic therapies, structural heart disease, peripheral intervention, and shock care are published simultaneously by JSCAI at SCAI 2026. These findings highlight the intersection of cardiometabolic management and structural heart care, with implications for patient outcomes.
A new study found that electronic provider notifications significantly increased aortic valve replacement rates and improved survival among older patients with severe symptomatic aortic stenosis. The DETECT-AS trial showed that clinicians who received automated email alerts with abnormal heart ultrasound results detected AS were more l...
The MitraClip procedure has been shown to be safe and effective for patients with mitral annular calcification, improving symptoms and quality of life. Despite higher mortality rates, patients with MAC experienced significant reductions in mitral regurgitation and improvements in quality of life, indicating a promising treatment option.
Partial heart transplantation replaces only defective valves and related structures, eliminating need for repeat replacements. This procedure can provide thousands of additional valve transplants annually, benefiting young patients worldwide.
Deaths from non-ischemic CS have risen sharply in the US, while ischemic CS deaths declined between 1999-2020. Researchers warn of a growing public health challenge that requires policy initiatives and targeted trials.
A multi-center retrospective cohort study examined how cangrelor is used in real-world clinical practice around the time of surgery following PCI. The study found that varying dosing patterns can affect outcomes, with higher infusion rates associated with increased bleeding events and lower infusion rates linked to higher major adverse...
A novel blood return system has been shown to significantly reduce blood loss during pulmonary embolism procedures, with a median reduction of 97%. The study found that the system improved procedural efficiency and maintained hemodynamic efficacy without added therapies or major complications.
Researchers found that elevated Lipoprotein(a) levels are associated with a higher risk of major adverse cardiovascular events, including stroke and death. Patients with high Lp(a) levels should work closely with their healthcare provider to aggressively lower LDL cholesterol and manage other cardiovascular risk factors.
A novel detection algorithm using finger cuff technology detected moderate-to-severe aortic stenosis with a sensitivity of 90.5% and 100% in African American patients, showing excellent performance for screening purposes.
New findings suggest that clopidogrel monotherapy is associated with a lower risk of net adverse clinical events compared to aspirin monotherapy, even in patients at high risk of bleeding. This benefit is more pronounced in patients with high bleeding risk and complex procedures.
A new study found that COVID-19 significantly worsens cardiovascular outcomes, leading to higher one-year mortality rates in patients with severe heart attacks. Patients who survived a heart attack and experienced COVID-19 had a 25% higher one-year mortality rate compared to those without COVID-19.
The CARPOOL study demonstrates radial-to-peripheral access achieves comparable procedural success rates to traditional common femoral artery access for lower extremity peripheral artery disease revascularization. However, the R2P group had higher major adverse limb events at six months due to target vessel revascularization.
A registry analysis found that while men and women with acute myocardial infarction-related cardiogenic shock differ in treatment options, clinical decisions are driven by objective markers of illness severity rather than sex. The study suggests significant differences in how treatment options are discussed with patients and caregivers.
Tirzepatide significantly reduces cardiovascular risk in high-risk patients, including those undergoing percutaneous coronary intervention (PCI) and transcatheter aortic valve replacement (TAVR). The study found tirzepatide consistently reduced major adverse cardiovascular events and mortality across multiple time points.
Researchers found that patients with single-vessel runoff maintained excellent patency through three years, and could safely benefit from minimally invasive treatment. The study results showed no significant difference in outcomes for patients with one or more vessels running blood to the lower leg.
The CERAMICS registry found that most patients survived hospital discharge, with 71% overall survival and 60% of those in the most severe stage E shock. Early use of a small heart pump improves outcomes in patients experiencing cardiogenic shock after a heart attack and stenting procedure.
The STEMI-DTU trial analyzed secondary endpoints, finding that major bleeding and vascular complications were associated with increased mortality in the control group. The study provided insight into the importance of technique and bleeding complications in heart attack treatments.
Transcatheter arterialization of the deep veins (TADV) significantly improves quality of life in patients with severe CLTI, reducing concerns about poor circulation and daily activities. Six months post-procedure, patients showed a 50% reduction in circulation concerns, improved sleep patterns, and reduced foot wound symptoms.
A new sub-study suggests that using a sirolimus-eluting balloon can reduce the number of stents needed, making it a safe and effective way to treat certain heart attacks or unstable chest pain. At one year, the rates of target vessel failure and cardiac death were low and similar between the two groups.
Researchers found a significant increase in TAVR search volume and a decline in SAVR searches over the past decade, reflecting a shift towards minimally invasive therapies. The study also highlighted disparities in awareness across rural and low-volume treatment areas.
A new transcatheter mitral valve replacement (TMVR) procedure has shown significant benefits for patients with severe mitral regurgitation, reducing symptoms and improving quality of life. The study found that the treatment sustained clinical improvements over one year, with no major complications.
A new global allocation system is being proposed to address inequities in organ allocation for heart transplants. The proposal aims to reduce disparities and ensure no viable donor heart goes unused globally.
A study found that higher midlife cardiorespiratory fitness is strongly associated with later onset of chronic disease, lower overall disease burden, and longer life expectancy. Adults with higher fitness levels developed fewer chronic diseases and spent more years free from serious illness.
The American College of Cardiology recognized 20 individuals from eight countries for earning the Fellow of ACC (FACC) designation. The award reflects a strong commitment to improving patient care and advancing cardiovascular research.
Researchers created a new polymer electrode that conforms to the skin, is comfortable, and can pick up ECG signals without gel or adhesives. The technology performed comparably to existing sensors in proof-of-concept testing, showcasing its potential for practical and cost-effective health monitoring applications.
A study analyzing Korean National Health and Nutrition Examination Survey data reveals higher awareness and treatment of major risk factors among Korean women with CVD, but lower control rates. Sex differences were observed in most management indicators, with men having more risk factors on average.
A study from Umeå University found that visualizing ultrasound images of atherosclerosis, combined with a motivational dialogue, increases motivation to improve lifestyle habits and take preventive medication. This results in lower estimated risk of cardiovascular disease and better development of risk factors over time.
Researchers at University Hospitals Cleveland Medical Center have introduced a new, non-invasive treatment option for patients with refractory ventricular tachycardia, a life-threatening heart condition. The therapy uses precision-targeted radiation to neutralize damaged heart tissue and is offered at select centers worldwide.
Alexandra J. Lansky, MD, MSCAI, has been reappointed to a second five-year term as Editor-in-Chief of JSCAI, the official peer-reviewed journal of SCAI. The journal has rapidly expanded its global reach and established itself as a trusted source for original research, clinical guidance, and educational content in interventional cardiol...
The conference brings together leading experts to examine emerging trends and evidence-based approaches to preventing and managing heart disease. Cardiometabolic disease accounts for a significant burden in the Asia-Pacific region, with rapid urbanization, digitalization, and uneven health-system capacity contributing to this issue.
The Society for Cardiovascular Angiography & Interventions and Canadian Association of Interventional Cardiology will host a joint conference featuring the latest clinical data, procedural guidance, and advanced expertise. The event aims to empower clinicians with rigorous data, practical education, and leadership development.
EuroPCR 2026 will feature 4 days of quality content, case-based learning sessions, and interactive formats. The course is designed for all levels of experience, covering topics in interventional cardiology, nursing, and research. EuroPCR aims to advance the quality of interventional practice and provide a transformative experience.
Treatment with i.v. furosemide plus HSS significantly decreased serum levels of inflammatory biomarkers IL-6, sST2, hsTnT, galectin-3, and NT-proBNP. The study found that this combination therapy modulated some miRNA expression and was associated with reduced miR181b expression compared to furosemide alone.
East Campus Medical Center has doubled its average daily census since 2024, with over 4,000 patients transferring to the hospital from other UC San Diego Health locations. The hospital now offers expanded services in cardiology, gastroenterology, and more, with a focus on continuity and relationship-based medicine.
A meta-analysis of GLP-1 receptor agonist studies found potential safety signals for gastrointestinal side effects, while some evidence suggested a link to reduced respiratory disease risk. Further research is needed to confirm the latter association.
Early and continuous acoramidis treatment resulted in sustained incremental reductions in all-cause mortality, cardiovascular-related mortality, and first cardiovascular hospitalization. The findings support the importance of early and continuous long-term treatment with acoramidis in transthyretin amyloid cardiomyopathy.
Dr. Roxana Mehran was appointed President of the American College of Cardiology, focusing on innovation, equity, and global collaboration to advance cardiovascular care. She aims to improve heart health for all through partnerships with major organizations.
Dr. Roxana Mehran begins a one-year term as president of the American College of Cardiology, leading a global organization with over 60,000 members. She aims to strengthen partnerships and foster growth, opportunity, and impact.
The new brain–heart clinical practice guideline provides a holistic approach to managing chronic diseases by integrating neurologic and mental health evidence with cardiovascular guidance. The guideline aims to improve the management of patients with concurrent brain and heart diseases, which often co-occur and share similar risk factors.
Dr. Renuka Jain has been appointed as the new chair of the American College of Cardiology Board of Governors, a role that will empower governors and strengthen Chapter foundations. Her priorities include setting up governors for success, strengthening advocacy at state and national levels, and creating leadership pipelines.
The study found that women with pregnancy-associated spontaneous coronary artery dissection (P-SCAD) have a higher risk of cardiovascular events, including dissections and aneurysms. Women with P-SCAD also experienced less recovery in left ventricular ejection fraction compared to those without P-SCAD.
The SPIRIT-HF trial found that spironolactone did not improve outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and mildly reduced ejection fraction (HFmrEF). The study also raised safety concerns about the use of spironolactone in older patients with heart failure.
The ORBITA-CTO trial found that angioplasty reduced angina episodes and improved quality-of-life scores in patients with chronic total occlusion. Patients who received CTO angioplasty were four times more likely to experience improved angina scores, with a significant reduction in angina-free days.
Patients who received temporary heart pump had almost double the risk of dying from a cardiovascular event compared to those receiving standard care. The study found no evidence that the device protected the heart during the angioplasty procedure.
Patients with atrial fibrillation have a higher risk of adverse cardiovascular events, including stroke, heart attack, and cardiac arrest. Serum neurofilament light chain levels can serve as a biomarker for cardiovascular risk in these patients.
A novel minimally invasive method for determining fatty deposits in coronary arteries restricting blood flow has produced similar outcomes to conventional FFR, according to a European randomized trial. The technique, called vessel FFR, uses computer analysis of three-dimensional images to calculate blood-flow restriction severity.
A Phase 2 trial found significant benefits for patients with poor prognosis and limited options, including improved six-minute walking distance and right heart function, and a lower rate of clinical worsening events. Sotatercept reduced pulmonary vascular resistance and showed a favorable safety profile.
A minimally invasive procedure using a clip to repair the valve significantly reduced heart failure hospitalizations by 40% in patients with severe tricuspid regurgitation. The study, presented at the American College of Cardiology's Annual Scientific Session, showed improved long-term outcomes without crossover between treatment groups.
A minimally invasive procedure to insert a new valve showed lower one-year event rates for death or disabling stroke compared to traditional repeat mitral valve replacement surgery. The study found that transcatheter mitral valve-in-valve (mVIV) reduced in-hospital deaths, acute kidney injury, and life-threatening bleeding complications.
Extended low-dose apixaban effectively reduced symptomatic superficial vein thrombosis (SuVT) risk. Patients with enduring risk factors for SuVT benefited from this anticoagulation strategy.
A novel software-based method combines AI to evaluate plaque restriction in coronary arteries, producing similar clinical outcomes as the gold standard wire-based procedure. The FFRangio technique eliminated additional procedural steps and was faster to perform.
A new study led by NYU Langone Health finds that combining advanced imaging tests can identify the underlying cause of heart attacks in most patients without blocked arteries. The research used coronary optical coherence tomography (OCT) and cardiac magnetic resonance imaging (MRI) to reveal a likely cause in 79 percent of patients.
A small study found mavacamten significantly improved left ventricular outflow tract gradient and symptoms in adolescents with obstructive HCM. The treatment may also reverse some heart damage and favorably remodel the heart, suggesting potential benefits for children diagnosed with the disease.
The PRO-TAVI study found that older, high-risk patients can safely defer percutaneous coronary intervention (PCI) until after transcatheter aortic valve replacement (TAVR), with comparable outcomes between the two groups. Omitting PCI before TAVR did not increase the risk of death, heart attack, stroke, or moderate to severe bleeding.
In high-risk patients without known significant atherosclerosis and with diabetes, evolocumab significantly reduced the risk of a first major cardiovascular event. The study found that evolocumab was effective in preventing cardiovascular events in these patient populations.
The EMPEROR-Preserved risk model demonstrated good performance in the FINEARTS-HF trial, showing that baseline risk does not modify the relative treatment effect of finerenone. Finerenone has been shown to have a significant benefit for heart failure patients.
A post hoc analysis found that tirzepatide was associated with a lower incidence of a broad composite cardiovascular and kidney endpoint. The study compared tirzepatide with dulaglutide in patients with diabetes and established cardiovascular disease.
The MOMENTUM study found that 27% of patients with resistant hypertension have hypercortisolism, a condition characterized by elevated cortisol levels. This finding suggests that hypercortisolism may be an underlying cause of resistant hypertension, which impacts nearly 10 million patients in the US.
A post hoc analysis of the Finerenone Trial reveals that sudden death in heart failure was often preceded by modest worsening of symptoms and declining quality of life. The study suggests limited specificity for sudden death among other modes of death, implying a complex trajectory before modes of death.